This is not the most recent version of the article. View current version (26 JUN 2014)

Intervention Protocol

Different infusion durations for preventing platinum-induced hearing loss in children with cancer

  1. Jorrit W van As1,*,
  2. Henk van den Berg2,
  3. Elvira C van Dalen2

Editorial Group: Cochrane Childhood Cancer Group

Published Online: 17 DEC 2013

DOI: 10.1002/14651858.CD010885


How to Cite

van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD010885. DOI: 10.1002/14651858.CD010885.

Author Information

  1. 1

    Emma Children's Hospital / Academic Medical Center, c/o Cochrane Childhood Cancer Group, Amsterdam, Netherlands

  2. 2

    Emma Children's Hospital / Academic Medical Center, Department of Paediatric Oncology, Amsterdam, Netherlands

*Jorrit W van As, c/o Cochrane Childhood Cancer Group, Emma Children's Hospital / Academic Medical Center, PO Box 22660, Amsterdam, 1100 DD, Netherlands. Jorritvas@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 17 DEC 2013

SEARCH

This is not the most recent version of the article. View current version (26 JUN 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of any platinum infusion duration to prevent hearing loss and/or tinnitus in children with cancer treated with platinum-based therapy (i.e. including cisplatin, carboplatin and/or oxaliplatin) when compared to another infusion duration. We will also assess possible effects of these infusion durations on anti-tumour efficacy (i.e. tumour response and survival) of platinum-based therapy, on adverse effects other than hearing loss and/or tinnitus and on quality of life.